Hemophilia is a rare genetic disorder that impairs the blood's ability to clot, leading to excessive bleeding. It affects approximately 1 in 6,000-10,000 males globally, with hemophilia A occurring 1 in 5,000 and hemophilia B affecting 1 in 30,000. There is a high unmet clinical need for better therapies, as current treatment options, such as clotting factor replacement, face limitations like short half-lives and the development of inhibitors. The increasing focus on gene therapies, bispecific antibodies, and RNA-based treatments is driving innovation in drug development. Several promising hemophilia drug candidates, including gene therapy products, are in the pipeline, offering hope for long-term disease management.
The Hemophilia Drug Pipeline Insight Report by Expert Market Research provides comprehensive insights into hemophilia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hemophilia. The hemophilia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hemophilia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hemophilia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hemophilia.
Hemophilia is a rare genetic disorder in which the blood doesn’t clot properly due to clotting factor VIII (Hemophilia A) or IX (Hemophilia B) deficiency. It is an X-linked recessive condition, mainly affecting males. Mutations in the F8 or F9 gene cause prolonged bleeding, spontaneous hemorrhages, and joint damage.
Hemophilia treatment includes factor replacement therapy, gene therapy, and bispecific antibodies like Emicizumab. Antifibrinolytics and recombinant factors improve bleeding control. Advancements in hemophilia therapeutic products are anticipated to reduce complications and the frequency of infusion.
Hemophilia affects approximately 1 in 6,000-10,000 males worldwide, with hemophilia A occurring in 1 in 5,000 and hemophilia B in 1 in 30,000. In the United States, an estimated 33,000 males have hemophilia. The United Kingdom reported approximately 6,662 cases of hemophilia A and 1,342 hemophilia B cases. In India, the prevalence is around 0.7 per 100,000, with 54,454 diagnosed cases.
This section of the report covers the analysis of hemophilia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total hemophilia clinical trials.
The drug molecule categories covered under the hemophilia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, RNA-based therapies, and cell-based therapies. The hemophilia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hemophilia.
The EMR report for the hemophilia drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed hemophilia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is a list of a few players involved in hemophilia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hemophilia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hemophilia drug candidates.
Nuwiq® (simoctocog alfa), a recombinant factor VIII (rFVIII) therapy developed by Octapharma, is under Phase IV clinical development for bleeding prevention in women and girls with hemophilia A undergoing major surgery. Nuwiq®, designed for personalized prophylaxis, has shown superior bleed prevention compared to other rFVIII products in indirect comparisons. This open-label, multinational study assesses perioperative efficacy in patients over 12 and is estimated to be completed by December 2025.
Mim8 (denecimig), a next-generation, fully human bispecific IgG4 antibody designed to mimic factor VIII activity and prevent bleeding episodes, is being evaluated in a Phase 3 FRONTIER4 study sponsored by Novo Nordisk A/S. The study aims to assess its long-term safety and efficacy in hemophilia A patients, with or without inhibitors. Administered subcutaneously weekly, biweekly, or monthly, the study aims to evaluate its impact on annualized bleeding rates and safety, lasting up to 5.5 years. This open-label extension study is expected to be completed by 2028.
SerpinPC, a subcutaneous inhibitor of activated protein C (APC), is being evaluated in a Phase 2 clinical trial (PRESent-2, NCT05789524) sponsored by ApcinteX Ltd. The study aims to assess the efficacy, safety, and pharmacokinetics of SerpinPC in patients with severe hemophilia A or moderately severe to severe hemophilia B, with the goal of reducing bleeding rates. This adaptive study includes dose justification, confirmation, and an extension phase. With a novel mechanism of action, SerpinPC offers a promising alternative to existing hemophilia therapies.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hemophilia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hemophilia. It offers necessary information for making informed investment decisions along with research, development, and strategic planning efforts. Stakeholders will benefit from the essential insights into hemophilia collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share